Replies to post #454089 on Anavex Life Sciences Corp (AVXL)

[crescentmotor]

Turns out the situation may not be as black and white as you suggest.

As my posting history confirms, I have on multiple instances used the term "failure" in the EXCELLENCE trial in the context of its failure to meet endpoints as confirmed/stated by AVXL. There is nothing nuanced about that. Whether or not a failure to meet endpoints could still ultimately result in regulatory approval, and under what circumstances, is an entirely different discussion dependent on a host of other factors and remains totally uncertain. It is extremely clear that the markets viewed the EXCELLENCE trial as a failure. That is the bottom line and all the word salads in the world won't erase the resultant 35% drop in AVXL's stock price. Sometimes a 30,000 foot view will add clarity. It's really not necessary to stomp around in the weeds.